dr. el-khoueiry on choosing between lenvatinib and sorafenib in hcc
Published 5 years ago • 1.2K plays • Length 1:22Download video MP4
Download video MP3
Similar videos
-
2:32
dr. el-khoueiry on choosing between immunotherapy agents and tkis in hcc
-
1:35
dr. el-khoueiry on evolving role of immunotherapy in hcc
-
1:38
dr. el-khoueiry discusses research on biomarkers in hcc
-
1:40
comparing sorafenib and lenvatinib for the frontline treatment of advanced hcc
-
1:16
dr. el-khoueiry on the frontline treatment landscape in hcc
-
1:41
dr. armaghany on frontline sorafenib versus lenvatinib in unresectable hcc
-
2:27
dr. el-khoueiry on immunotherapy combinations in hcc
-
5:59
frontline lenvatinib vs sorafenib in hcc
-
1:42
dr. el-khoueiry on the role of ramucirumab in advanced hcc
-
6:51
hcc: use of lenvatinib and sorafenib
-
1:38
dr. finn on significance of phase iii findings of lenvatinib in hcc
-
7:38
frontline clinical trials in liver cancer
-
1:58
anthony el-khoueiry, md, discusses management of nexavar (sorafenib) toxicities in hcc
-
4:37
options following sorafenib in hcc
-
1:28
dr. el-khoueiry on the rationale for evaluating nivolumab in advanced hcc
-
6:02
hcc: considerations in first-line use of sorafenib
-
6:53
sequencing in dtc: lenvatinib and sorafenib
-
8:10
dosing strategies with sorafenib in hcc
-
1:22
dr. cheng on phase iii findings of lenvatinib in hcc